Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/178)
-
Patent number: 8921348Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.Type: GrantFiled: October 29, 2013Date of Patent: December 30, 2014Assignee: Corcept Therapeutics, Inc.Inventor: Joseph K. Belanoff
-
Publication number: 20140378424Abstract: The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (ERM), optionally, in combination with an anti-obesity or weight loss agent.Type: ApplicationFiled: December 31, 2012Publication date: December 25, 2014Inventors: Alexey G Ryazanov, Alexander V. Chikunov
-
Publication number: 20140374516Abstract: Disclosed is a process for the preparation of drug/carrier inclusion composites which involves co-grinding the mixture of drug and carrier powders in a fluid-jet mill, in particular one using air or nitrogen as the fluid, which is suitably modified to allow mechanical fusion of the powders.Type: ApplicationFiled: January 25, 2013Publication date: December 25, 2014Applicant: MICRO-MACINAZIONE S.A.Inventors: Fabio Carli, Piero Iamartino, Milko Leone
-
Publication number: 20140371189Abstract: A method of treating an animal which does not naturally produce sufficient quantities of testosterone includes periodically administering a testosterone to the animal. The method includes conducting an initial examination of the animal; determining a testosterone level of the animal; administering a testosterone to the animal; determining the testosterone level of the animal to which the testosterone has been administered; and periodically administering the testosterone to the animal and monitoring the testosterone level, based on the detected testosterone levels and clinical signs.Type: ApplicationFiled: February 24, 2014Publication date: December 18, 2014Applicant: DAVID BIEBER CONSULTING, LLCInventor: David Bieber
-
Publication number: 20140364379Abstract: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.Type: ApplicationFiled: July 26, 2012Publication date: December 11, 2014Applicant: Allergan Inc.Inventors: Anuradha V. Gore, Sai Shankar, Sukhon Likitiersuang, Chetan P. Pujara, Sesha Neervanna
-
Publication number: 20140357586Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventor: Mahesh V. Patel
-
Patent number: 8900631Abstract: A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability. In contrast to the approach taught by the prior art, the instant approach is amenable to scale-up to commercial scale. Further, the resulting product is amenable to analysis using standard, known quantitative analytical techniques; thus, unlike the prior art approach, the instant approach may be used to manufacture a product in conformity with applicable regulatory standards.Type: GrantFiled: April 23, 2012Date of Patent: December 2, 2014Assignee: Health Science Funding, LLCInventor: J. Mark Pohl
-
Publication number: 20140348854Abstract: The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases.Type: ApplicationFiled: June 6, 2012Publication date: November 27, 2014Applicant: WOMEN & INFANTS' HOSPITAL OF RHODE ISLANDInventors: Richard G. Moore, Rakesh K. Singh
-
Publication number: 20140343026Abstract: A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability. In contrast to the approach taught by the prior art, the instant approach is amenable to scale-up to commercial scale. Further, the resulting product is amenable to analysis using standard, known quantitative analytical techniques; thus, unlike the prior art approach, the instant approach may be used to manufacture a product in conformity with applicable regulatory standards.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Applicant: HEALTH SCIENCE FUNDING, LLCInventor: J. Mark POHL
-
Publication number: 20140343025Abstract: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.Type: ApplicationFiled: March 4, 2014Publication date: November 20, 2014Applicant: FCB I, LLCInventor: Robert J. Gyurik
-
Publication number: 20140335153Abstract: A method of preparing a thin film, the method comprising: (a) mixing a lipid, emulsifier, and solvent to provide a uniform first mixture; (b) contacting an active ingredient with the uniform first mixture to provide a thickened second mixture; (c) contacting a binder with the thickened second mixture to provide a slurry; and (d) hot extruding, casting, and condensing the slurry to provide the thin film; or cooling, shearing, mixing, casting, and condensing the slurry to provide the thin film.Type: ApplicationFiled: October 31, 2013Publication date: November 13, 2014Applicant: CURE Pharmaceutical CorporationInventors: Eric Allen, Robert Steven Davidson, Jose Bernardo
-
Publication number: 20140329788Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 31, 2014Publication date: November 6, 2014Applicants: Besins Healthcare Luxembourg SARL, Unimed Pharmaceuticals, LLCInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140329789Abstract: This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventor: James A. Carnazza
-
Patent number: 8877236Abstract: New liposomes are described, comprising: (i) phosphatidic acid and/or cardiolipin; (ii) apolipoprotein E (ApoE) or derivatives thereof. The so modified liposomes, administered systemically, obtain a dramatic in-vivo reduction of the amyloid plaque in the central nervous system, allowing an effective treatment of neurodegenerative diseases, in particular Alzheimer's disease.Type: GrantFiled: June 28, 2012Date of Patent: November 4, 2014Assignee: Universita Degli Studi di Milano-BicoccaInventors: Massimo Masserini, Francesca Re, Giulio Sancini, Gianluigi Forloni, Mario Salmona
-
Patent number: 8877230Abstract: This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.Type: GrantFiled: December 10, 2011Date of Patent: November 4, 2014Assignee: Mattern Pharma AGInventor: Claudia Mattern
-
Publication number: 20140323452Abstract: The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure wherein R is —C13H25O or —C14H27O. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone Cavg t12-t24 that is within about 35% to about 70% of the mean serum testosterone Cavg t0-t24.Type: ApplicationFiled: June 30, 2014Publication date: October 30, 2014Inventors: Satish Kumar Nachaegari, Chandrashekar Giliyar, Raj Patel, Chidambaram Nachiappan, Srinivasan Venkateshwaran, Mahesh V. Patel
-
Publication number: 20140323453Abstract: The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure wherein R is —C13H25O or —C14H27O. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone Cavg t12-t24 that is within about 35% to about 70% of the mean serum testosterone Cavg t0-t24.Type: ApplicationFiled: June 30, 2014Publication date: October 30, 2014Inventors: Satish Kumar Nachaegari, Chandrashekar Giliyar, Raj Patel, Chidambaram Nachiappan, Srinivasan Venkateshwaran, Mahesh V. Patel
-
Publication number: 20140315872Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.Type: ApplicationFiled: March 17, 2014Publication date: October 23, 2014Applicant: Allergan, Inc.Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
-
Publication number: 20140314815Abstract: The present invention is drawn to adhesive solid gel-forming formulations, methods of drug delivery, and solidified gel layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a gelling agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified gel layer after at least a portion of the volatile solvent system is evaporated. The solidified gel layer is can be removed by peeling or washing.Type: ApplicationFiled: January 22, 2014Publication date: October 23, 2014Applicant: Nuvo Research Inc.Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20140315833Abstract: A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.Type: ApplicationFiled: April 21, 2014Publication date: October 23, 2014Inventors: Anders Berkenstam, Edward Kuczynski, Alf S. Andersson, Jan-Ake Gustafsson, Carly Sue Filgueira
-
Patent number: 8865690Abstract: 17?,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17?,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters thereof having remarkable antiandrogenic activity, and the processes for the preparation thereof.Type: GrantFiled: December 11, 2013Date of Patent: October 21, 2014Assignee: Cosmo Dermatos SrlInventors: Mauro Ajani, Luigi Moro
-
Patent number: 8865695Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.Type: GrantFiled: February 26, 2014Date of Patent: October 21, 2014Assignee: Lipocine Inc.Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
-
Publication number: 20140309202Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.Type: ApplicationFiled: June 6, 2014Publication date: October 16, 2014Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Chidambaram Nachiappan, Mahesh V. Patel
-
Publication number: 20140303130Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.Type: ApplicationFiled: June 6, 2014Publication date: October 9, 2014Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Chidambaram Nachiappan, Mahesh V. Patel
-
Publication number: 20140303128Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the hormone testosterone, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.Type: ApplicationFiled: March 14, 2014Publication date: October 9, 2014Inventor: John McCarty
-
Publication number: 20140303129Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. The methods are designed toprovide optimum serum testosterone levels over an extended period.Type: ApplicationFiled: March 17, 2014Publication date: October 9, 2014Applicant: Clarus Therapeutics, Inc.Inventors: Robert E. Dudley, Panayiotis P. Constantinides, James A. Longstreth
-
Publication number: 20140296198Abstract: Biomarkers associated with anti-estrogen sensitivity in cancers, methods for detecting and quantitating the biomarkers, and methods for treating cancer patients that exhibit the biomarkers are provided. The biomarkers are activated estrogen receptor foci (AEF) found in the nuclei of certain tumor cells. The methods provide new information to guide the intention to treat patients with anti-estrogens, allowing selection of individual patients and patient populations that are likely to respond to treatment. Also provided are methods for screening an antitumor drug or antitumor drug candidate for AEF inactivating activity. Such methods are useful to identify additional AEF-active drugs, including anti-estrogens, which may be candidates for use in treating AEF-positive tumors according to the methods of the invention.Type: ApplicationFiled: November 1, 2012Publication date: October 2, 2014Inventor: Erard Gilles
-
Publication number: 20140296191Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Applicant: THEMIS MEDICARE LIMITEDInventors: Dinesh Shantilal PATEL, Sachin Dinesh PATEL, Shashikant Prabhudas KURANI, Madhavlal Govindlal PATEL
-
Publication number: 20140288038Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.Type: ApplicationFiled: December 19, 2013Publication date: September 25, 2014Applicant: Noven Pharmaceuticals, Inc.Inventor: David Kanios
-
Publication number: 20140287988Abstract: Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder.Type: ApplicationFiled: December 9, 2013Publication date: September 25, 2014Applicant: ALLERGAN, INC.Inventors: ANURADHA V. GORE, KEVIN S. WARNER, CHETAN P. PUJARA, RICHARD S. GRAHAM, AJAY P. PARASHAR, MU-LAN LEE, ROBERT S. JORDAN, SUKHON LIKITLERSUANG
-
Publication number: 20140288039Abstract: The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 30, 2014Publication date: September 25, 2014Applicant: Lipocine Inc.Inventors: Satish Kumar Nachaegari, Chandrashekar Giliyar, Raj Patel, Chidambaram Nachiappan, Srinivasan Venkateshwaran, Mahesh V. Patel
-
Publication number: 20140271882Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.Type: ApplicationFiled: April 24, 2014Publication date: September 18, 2014Applicant: Lipocine Inc.Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Chidambaram Nachiappan, Mahesh V Patel
-
Patent number: 8835413Abstract: Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance , in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.Type: GrantFiled: October 20, 2005Date of Patent: September 16, 2014Assignee: Endorecherche, Inc.Inventors: Mohamed El-Alfy, Fernand Labrie, Louise Berger
-
Patent number: 8835376Abstract: A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form; and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient.Type: GrantFiled: September 24, 2009Date of Patent: September 16, 2014Assignee: Nanomaterials Technology Pte LtdInventors: Zhigang Shen, Jimmy Sung Lai Yun, Jun Hu, Nital Arvind Jugade, Jiyao Zhang, Wenhao Chen, Zhe Wang, Lingyan Gao, William Glover, Jian Feng Chen
-
Publication number: 20140249123Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.Type: ApplicationFiled: February 26, 2014Publication date: September 4, 2014Applicant: Allergan, Inc.Inventors: Thierry Nivaggioli, Jane-Guo Shiah, Qing Lin
-
Publication number: 20140249124Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.Type: ApplicationFiled: April 16, 2014Publication date: September 4, 2014Applicant: Clarus Therapeutics, Inc.Inventors: Robert E. Dudley, Panayiotis P. Constantinides
-
Publication number: 20140249120Abstract: The present disclosure is generally directed to neuroactive 13,17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: February 27, 2014Publication date: September 4, 2014Applicant: WASHINGTON UNIVERSITYInventors: Douglas Covey, Xin Jiang
-
Publication number: 20140235598Abstract: The present invention relates to a tablet having a weight of 30-200 mg and consisting of: 60-100 wt. % of granules consisting of: 50-90% by weight of the granules of dehydroepiandrosterone (DHEA); 6-35% by weight of the granules of microcrystalline cellulose; 0-20% by weight of the granules of one or more other pharmaceutically acceptable granule ingredients; and 0-40 wt. % of one or more other pharmaceutically acceptable tablet components. These tablets can suitably be used to orally administer DHEA in dosages of around 50 mg and are sufficiently small to be incorporated in, for instance, ordinary oral contraceptive blister packs.Type: ApplicationFiled: July 17, 2012Publication date: August 21, 2014Inventors: Herman Jan Tijmen Coelingh Bennink, Johannes Jan Platteeuw
-
Publication number: 20140234428Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Applicant: Cymbiotics, Inc.Inventors: Raj R. Barathur, Jack Bain Bookout
-
NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
Publication number: 20140235600Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: December 18, 2013Publication date: August 21, 2014Applicant: Washington UniversityInventors: Douglas Covey, Albert Jean Robichaud -
Publication number: 20140235601Abstract: The use of an aromatase blocker or an estrogen blocker is described in a method for increasing spermatogenesis and Seritolli cell function, and/or improving Leydig cell function, in order to to increase endogenous testosterone levels in a male mammal. The levels of active materials used are significantly lower than the levels of these materials used to treat female estrogen sensitive tumors.Type: ApplicationFiled: August 9, 2012Publication date: August 21, 2014Inventor: Kenneth W. Adams
-
Patent number: 8802660Abstract: The present invention relates to methods and compositions that control, i.e., antagonize/inhibit or agonize/stimulate, de novo glucocorticoid production in the skin. Such methods and compositions can be used for the prevention and/or treatment of a variety of skin conditions, including inflammation, acute wounds, chronic non-healing wounds, keloid, fibrotic or hypertrophic scars, and epithelial-derived cancer.Type: GrantFiled: March 12, 2008Date of Patent: August 12, 2014Assignee: New York UniversityInventors: Marjana Tomic-Canic, Harold Brem, Herbert H. Samuels
-
Publication number: 20140206657Abstract: Provided herein are bile acid analogues and derivatives, methods of synthesizing bile acid analogues and derivatives and their use in treating diabetes and liver disease.Type: ApplicationFiled: January 21, 2014Publication date: July 24, 2014Applicant: City of HopeInventors: Donna Yu, Barry Forman, Wendong Huang, Kyle Sousa
-
Patent number: 8785425Abstract: The invention provides 11?-hydroxyandrosta-4-ene-3-one compounds of Formula I, or physiologically acceptable salts or solvates thereof: wherein R4 represents a moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C), Z is S:Type: GrantFiled: July 25, 2008Date of Patent: July 22, 2014Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Jiten Ranchhodbhai Patel, Gopalkumar Chimanlal Patel, Gaurav Sanjivkumar Sheth, Samir Rameshchandra Shah, Sanjay Nandlal Mandhane, Trinadha Rao Chitturi, Rajamannar Thennati
-
Patent number: 8785426Abstract: Described are gel compositions containing active pharmaceutical ingredient such as testosterone, solvent, and thickener, the gel compositions being useful for transdermal administration of the active ingredient to a patient, and related methods. Certain embodiments of the gel composition specifically exclude Hsieh enhancer.Type: GrantFiled: February 11, 2014Date of Patent: July 22, 2014Assignee: Upsher-Smith Laboratories, Inc.Inventor: Harish K. Pimplaskar
-
Patent number: 8784869Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: GrantFiled: July 12, 2012Date of Patent: July 22, 2014Assignee: Mattern Pharma AGInventor: Claudia Mattern
-
Publication number: 20140200200Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.Type: ApplicationFiled: May 18, 2012Publication date: July 17, 2014Applicants: UNIVERSITE DE BORDEAUX I, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIV DE BORDEAUX II VICTOR SEGALENInventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
-
Publication number: 20140200531Abstract: Aspects of the present invention concern the discovery of a transdermal delivery composition that can deliver low, medium and high molecular weight pharmaceuticals and cosmetic agents. Embodiments include transdermal delivery compositions with therapeutic and cosmetic application, transdermal delivery devices for providing said transdermal delivery compositions to subjects in need thereof, and methods of making and using of the foregoing.Type: ApplicationFiled: December 19, 2013Publication date: July 17, 2014Applicant: JRX Biotechnology, Inc.Inventors: Frederick Jordan, Geoff E. Dolbear
-
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Patent number: 8778916Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.Type: GrantFiled: August 14, 2012Date of Patent: July 15, 2014Assignee: Clarus Therapeutics, Inc.Inventors: Robert E. Dudley, Panayiotis P. Constantinides -
Patent number: 8778917Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.Type: GrantFiled: September 13, 2013Date of Patent: July 15, 2014Assignee: Clarus Therapeutics, Inc.Inventors: Robert E. Dudley, Panayiotis P. Constantinides